CSF1R and glioblastoma: Additionally, combining CSF-1R blockade with ICIs has shown enhanced therapeutic efficacy by overcoming macrophage-mediated immunosuppression.315 Thus, targeting CSF-1R signaling represents a promising strategy for GBM immunotherapy.